-
Company Insights
Innovation and Patenting activity of Zydus Wellness Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Zydus Wellness Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Desidustat in Chemotherapy Induced Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Desidustat in Chemotherapy Induced Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Desidustat in Chemotherapy Induced Anemia Drug Details: Desidustat (Oxemia) is an erythropoietin-stimulating...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Hypertriglyceridemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Hypertriglyceridemia Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Cholestasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Cholestasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Cholestasis Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Liver Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Liver Diseases report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Liver Diseases Drug Details: Saroglitazar (lipaglyn) is the first...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
Rubella (German Measles) – Drugs In Development, 2023
Global Markets Direct’s, ‘Rubella (German Measles) - Drugs In Development, 2023’, provides an overview of the Rubella (German Measles) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rubella (German Measles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Rubivirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Rubivirus Infections - Drugs In Development, 2023’, provides an overview of the Rubivirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rubivirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hepatitis A – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis A - Drugs In Development, 2023’, provides an overview of the Hepatitis A pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hepatovirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatovirus Infections - Drugs In Development, 2023’, provides an overview of the Hepatovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...